Feasibility of Fluorescence Imaging with Bevacizumab-800CW During Bronchoscopy

Launched by UNIVERSITY MEDICAL CENTER GRONINGEN · Jan 30, 2025

Keywords

ClinConnect Summary

This clinical trial is exploring a new way to help doctors see lung tumors and affected lymph nodes during a procedure called bronchoscopy. In this study, a special imaging technique using a dye called bevacizumab-800CW will be tested to see if it makes it easier to identify cancerous growths in the lungs. The goal is to find out if this method can improve the detection of lung cancer and potentially help in planning treatment.

To participate in this trial, you must be at least 18 years old and have a suspicious growth in your lungs or nearby lymph nodes that is thought to be cancer. You also need to be healthy enough to undergo bronchoscopy, which may involve sedation or anesthesia. Before joining, you’ll be asked to sign a consent form to ensure you understand the process. If you have had serious reactions to bevacizumab in the past or have certain medical conditions that affect your ability to give consent, you may not be eligible for this study.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Signed informed consent prior to participation in the study.
• • 2. Age ≥ 18 years.
• • 3. Patient has at least one intrabronchial, near-to-airway located or peripheral pulmonary nodule - with or without pathological lymph nodes - which is considered malignant (independent of its primary origin).
• • 4. Patient is considered fit to undergo a diagnostic and/or therapeutic bronchoscopy (with or without addition of virtual navigation and/or endobronchial ultrasound; including propofol sedation or general anesthesia if either is indicated) to obtain tumor material according to standard care protocols.
• Exclusion Criteria:
• • 1. History of infusion reactions to bevacizumab.
• • 2. Medical or psychiatric conditions that compromise the patient's ability to give informed consent.